Vol 13: Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.Report as inadecuate



 Vol 13: Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.


Vol 13: Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 13: Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
This article is from Malaria Journal, volume 13.AbstractBackground: Malaria and HIV infections are both highly prevalent in sub-Saharan Africa, with HIV-infected patients being at higher risks of acquiring malaria. The majority of antiretroviral ART and anti-malarial drugs are metabolized by the CYP450 system, creating a chance of drug-drug interaction upon co-administration. Limited data are available on the effectiveness of the artemether-lumefantrine combination AL when co-administered with non-nucleoside reverse transcriptase inhibitors NNRTIs. The aim of this study was to compare anti-malarial treatment responses between HIV-1 infected patients on either nevirapine- or efavirenz-based treatment and those not yet on ART control-arm with uncomplicated falciparum malaria, treated with AL. Method: This was a prospective, non-randomized, open-label study conducted in Bagamoyo district, with three arms of HIV-infected adults: efavirenz-based treatment arm EFV-arm n = 66, nevirapine-based treatment arm NVP-arm n = 128, and control-arm n = 75, with uncomplicated malaria. All patients were treated with AL and followed up for 28 days. The primary outcome measure was an adequate clinical and parasitological response ACPR after treatment with AL by day 28. Results: Day 28 ACPR was 97.6%, 82.5% and 94.5% for the NVP-arm, EFV-arm and control-arm, respectively. No early treatment or late parasitological failure was reported. The cumulative risk of recurrent parasitaemia was 19-fold higher in the EFV-arm than in the control-arm Hazard ratio HR, 19.11 95% confidence interval {CI}, 10.5–34.5; P 



Author: Maganda, Betty A; Minzi, Omary MS; Kamuhabwa, Appolinary AR; Ngasala, Billy; Sasi, Philip G

Source: https://archive.org/







Related documents